Previous close | 1.4500 |
Open | 1.5300 |
Bid | 1.1500 |
Ask | 2.0500 |
Strike | 55.00 |
Expiry date | 2025-01-17 |
Day's range | 1.5300 - 1.5300 |
Contract range | N/A |
Volume | |
Open interest | 1.28k |
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the outcomes from HARMONIE, a p
Sanofi (NASDAQ:SNY) Q1 2024 Earnings Call Transcript April 25, 2024 Sanofi reports earnings inline with expectations. Reported EPS is $0.96 EPS, expectations were $0.96. Sanofi isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Paul Hudson: Welcome to the Q1 2024 conference […]